Lightlake Therapeutics Inc.
OTC Bulletin Board : LLTP

Lightlake Therapeutics Inc.

February 01, 2011 13:23 ET

Lightlake Therapeutics Takes Safer Approach to Obesity

LONDON, ENGLAND--(Marketwire - Feb. 1, 2011) - Lightlake Therapeautics ("Lightlake") (OTCBB:LLTP) After the recent FDA decision concerning Orexigen's obesity medicine, Contrave™ (naltrexone plus bupropion) Lightlake would like to clarify that they do not anticipate the same cardiovascular problems with their treatment of binge eating disorder with naloxone alone. 

Lightlake has found that opioid antagonists, such as naltrexone and naloxone, when used properly, are highly effective when used as single agents, for addictive behaviors such as binge eating. Opioid antagonists are particularly safe and the opioidergic system can be blocked with minimal side-effects.

"Lightlake's antagonist, naloxone, is "the safest antagonist available" [1]. In contrast to naltrexone that is given in a large daily dose sufficient to block the opioid system 24 hours a day, Lightlake uses a more precise method, administering a small dose of naloxone that is present in significant quantities for only about 2 hours, i.e., the typical duration of an eating binge, and only on the days when the patient is having an eating binge, leaving the body free of medication the rest of the time. Furthermore we only expect patients to be regularly using this medication on a daily basis for the first two weeks and on an ad hoc basis afterwards. Therefore patients will not be chronically exposed to our treatment. Naturally, we are monitoring cardiovascular measures in our Phase II clinical trial, but we do not anticipate any adverse effects." stated Dr. David Sinclair, Chief Scientific Officer.

(1) Sneader, Walter (2005) Drug Discovery: A History. Chichester, UK, Wiley, 468 p (quotation, p120.)

About Lightlake Therapeutics

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be completed during 2011. 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact Information


View Website